| Literature DB >> 31687280 |
Jingwei Liu1, Weixin Liu1, Hao Li1, Qiuping Deng1, Meiqi Yang1, Xuemei Li1, Zeng Liang1.
Abstract
BACKGROUND: As the most frequently occurred tumor in biliary tract, cholangiocarcinoma (CCA) is mainly characterized by its late diagnosis and poor outcome. It is therefore urgent to identify specific genes and pathways associated with its progression and prognosis.Entities:
Keywords: Cho; Cholangiocarcinoma; Prognosis; Progression; Weighted gene correlation network analysis
Year: 2019 PMID: 31687280 PMCID: PMC6825751 DOI: 10.7717/peerj.7968
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Interaction relationship analysis of co-expression genes in cholangiocarcinoma.
Figure 2The module–clinical trait relationships of genes involved in clinicopathological parameters of cholangiocarcinoma patients.
Gene ontology (GO) analysis of the genes involved in hub modules.
| Module | ID | Description | GeneRatio | Count | |
|---|---|---|---|---|---|
| tan | Heart valve morphogenesis | 5/181 | 3.36E-05 | 5 | |
| tan | NADP metabolic process | 5/181 | 3.36E-05 | 5 | |
| tan | Heart valve development | 5/181 | 5.67E-05 | 5 | |
| tan | Ventricular septum development | 6/181 | 5.83E-05 | 6 | |
| tan | Cardiac septum morphogenesis | 6/181 | 6.92E-05 | 6 | |
| tan | Cardiac septum development | 7/181 | 7.37E-05 | 7 | |
| tan | Fibroblast activation | 3/181 | 0.00013 | 3 | |
| tan | Response to acid chemical | 12/181 | 0.00015 | 12 | |
| tan | Wnt signaling pathway | 15/181 | 0.00016 | 15 | |
| tan | Cell-cell signaling by wnt | 15/181 | 0.00017 | 15 | |
| salmon | Digestion | 16/148 | 1.02E-12 | 16 | |
| salmon | Regulation of hormone levels | 22/148 | 1.53E-10 | 22 | |
| salmon | Hormone transport | 15/148 | 7.10E-08 | 15 | |
| salmon | Hormone secretion | 14/148 | 2.85E-07 | 14 | |
| salmon | Signal release | 16/148 | 6.22E-07 | 16 | |
| salmon | Peptide hormone secretion | 12/148 | 1.16E-06 | 12 | |
| salmon | Regulation of hormone secretion | 12/148 | 1.84E-06 | 12 | |
| salmon | Positive regulation of epithelial cell proliferation | 10/148 | 2.07E-06 | 10 | |
| salmon | Regulation of peptide hormone secretion | 10/148 | 8.73E-06 | 10 | |
| salmon | Epithelial cell proliferation | 13/148 | 1.32E-05 | 13 |
Figure 3Gene Ontology analysis for genes in the hub modules of tan module and salmon module in cholangiocarcinoma.
Figure 4The correlation between the expression levels of key genes of hub modules and the survival of CAA patients.
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis of the genes involved in hub modules.
| Module | ID | Description | GeneRatio | Count | |
|---|---|---|---|---|---|
| tan | hsa05224 | Breast cancer | 10/81 | 3.65E-06 | 10 |
| tan | hsa00480 | Glutathione metabolism | 6/81 | 2.84E-05 | 6 |
| tan | hsa04310 | Wnt signaling pathway | 8/81 | 0.00017 | 8 |
| tan | hsa05230 | Central carbon metabolism in cancer | 5/81 | 0.00066 | 5 |
| tan | hsa05226 | Gastric cancer | 7/81 | 0.00111 | 7 |
| tan | hsa04150 | mTOR signaling pathway | 7/81 | 0.0012 | 7 |
| salmon | hsa04972 | Pancreatic secretion | 11/64 | 3.74E-10 | 11 |
| salmon | hsa04974 | Protein digestion and absorption | 10/64 | 3.45E-09 | 10 |
| salmon | hsa05217 | Basal cell carcinoma | 3/64 | 0.01654 | 3 |
| salmon | hsa04360 | Axon guidance | 5/64 | 0.0167 | 5 |
| salmon | hsa00830 | Retinol metabolism | 3/64 | 0.01948 | 3 |
| salmon | hsa04380 | Osteoclast differentiation | 4/64 | 0.02372 | 4 |
| salmon | hsa04911 | Insulin secretion | 3/64 | 0.03605 | 3 |
| salmon | hsa04970 | Salivary secretion | 3/64 | 0.04162 | 3 |
| salmon | hsa04975 | Fat digestion and absorption | 2/64 | 0.04786 | 2 |
Key genes associated with prognosis of cholangiocarcinoma patients in hub modules.
| Gene | Full name | Module | HR | 95% CI | |
|---|---|---|---|---|---|
| SOX2 | SRY-box 2 | tan | 0.382 | [0.145–1.002] | 0.043 |
| KIT | KIT proto-oncogene receptor tyrosine kinase | tan | 0.341 | [0.132–0.883] | 0.048 |
| PRSS56 | Serine protease 56 | tan | 2.876 | [1.048–7.892] | 0.018 |
| WNT9A | Wnt family member 9A | tan | 0.389 | [0.144–1.050] | 0.041 |
| SLC4A4 | Solute carrier family 4 member 4 | tan | 0.352 | [0.133–0.931] | 0.025 |
| PRRG4 | Proline rich and Gla domain 4 | tan | 0.339 | [0.127–0.900] | 0.023 |
| PANX2 | Pannexin 2 | tan | 2.600 | [0.963–7.022] | 0.037 |
| PIR | Pirin | tan | 2.701 | [0.994–7.337] | 0.027 |
| RASSF8 | Ras association domain family member 8 | tan | 0.396 | [0.147–1.065] | 0.040 |
| MFSD4A | Major facilitator superfamily domain containing 4A | salmon | 0.371 | [0.143–0.962] | 0.043 |
| INS | Insulin | salmon | 4.670 | [0.458–47.564] | 0.006 |
| RNF39 | Ring finger protein 39 | salmon | 2.811 | [1.063–7.434] | 0.032 |
| IL1R2 | Interleukin 1 receptor type 2 | salmon | 0.379 | [0.144–0.997] | 0.041 |
| CST1 | Cystatin SN | salmon | 2.846 | [1.039–7.797] | 0.017 |
| PPP3CA | Protein phosphatase 3 catalytic subunit alpha | salmon | 3.151 | [1.129–8.793] | 0.010 |
Figure 5The correlation between the expression levels of key genes of hub modules and the survival of CAA patients.
(A) INS; (B) PPP3CA; (C) CST1; (D) RNF39; (E) PRSS56; (F) PRRG4; (G) SLC4A4; (H) PIR.
Figure 6The differential expression of potential hub genes in different stages of CCA patients.
(A) Differential expression of INS, PPP3CA, CST1 and RNF39; (B) Differential expression of PRSS56, PRRG4, SLC4A4 and PIR.
The association of prognosis-related genes with clinical of stage of cholangiocarcinoma patients.
| Gene symbol | Gene title | Position | OR | |
|---|---|---|---|---|
| MFSD4A | Major facilitator superfamily domain containing 4A | 1q32.1 | 1.036 (0.988–1.093) | 0.155 |
| SOX2 | SRY-Box 2 | 3q26.33 | 1.037 (0.986–1.115) | 0.184 |
| INS | Insulin | 11p15.5 | 1.125 (0.996–1.320) | 0.059 |
| KIT | KIT proto-oncogene receptor tyrosine kinase | 4q12 | 1.033 (0.991–1.091) | 0.146 |
| PRSS56 | Serine protease 56 | 2q37.1 | ||
| RNF39 | Ring finger protein 39 | 6p22.1 | ||
| WNT9A | Wnt family member 9A | 1q42.13 | 0.965 (0.904–1.018) | 0.235 |
| SLC4A4 | Solute carrier family 4 member 4 | 4q13.3 | 1.001 (0.973–1.029) | 0.945 |
| IL1R2 | Interleukin 1 receptor type 2 | 2q11.2 | 1.027 (0.993–1.068) | 0.131 |
| CST1 | Cystatin SN | 20p11.21 | 1.007 (0.988–1.026) | 0.490 |
| PRRG4 | Proline rich and Gla domain 4 | 11p13 | 0.983 (0.922–1.041) | 0.574 |
| PANX2 | Pannexin 2 | 22q13.33 | 0.987 (0.940–1.024) | 0.517 |
| PIR | Pirin | Xp22.2 | 0.983 (0.930–1.027) | 0.489 |
| RASSF8 | Serine protease 8 | 12p12.1 | 0.942 (0.863–1.002) | 0.094 |
| PPP3CA | Protein phosphatase 3 catalytic subunit alpha | 4q24 | 1.021 (0.960–1.086) | 0.492 |
Note:
The bold values indicate significant association between gene expression and clinical stage of CCA patients.